Riecke Kerstin, Müller Volkmar, Weide Rudolf, Schmidt Marcus, Park-Simon Tjoung-Won, Möbus Volker, Mundhenke Christoph, Polasik Arkadius, Lübbe Kristina, Hesse Tobias, Laakmann Elena, Thill Marc, A Fasching Peter, Denkert Carsten, Fehm Tanja, Nekljudova Valentina, Rey Julia, Loibl Sibylle, Witzel Isabell
Department of Gynecology, University Medical Center Hamburg-Eppendorf, Martinistraße 52, 20246 Hamburg, Germany.
Oncological Outpatient Department, Neversstraße 5, 56068 Koblenz, Germany.
Cancers (Basel). 2021 Feb 17;13(4):844. doi: 10.3390/cancers13040844.
Several scores have been developed in order to estimate the prognosis of patients with brain metastases (BM) by objective criteria. The aim of this analysis was to validate all three published graded-prognostic-assessment (GPA)-scores in a subcohort of 882 breast cancer (BC) patients with BM in the Brain Metastases in the German Breast Cancer (BMBC) registry. The median age at diagnosis of BM was 57 years. All in all, 22.3% of patients ( = 197) had triple-negative, 33.4% ( = 295) luminal A like, 25.1% ( = 221) luminal B/HER2-enriched like and 19.2% ( = 169) HER2 positive like BC. Age ≥60 years, evidence of extracranial metastases (ECM), higher number of BM, triple-negative subtype and low Karnofsky-Performance-Status (KPS) were all associated with worse overall survival (OS) in univariate analysis ( < 0.001 each). All three GPA-scores were associated with OS. The breast-GPA showed the highest probability of classifying patients with survival above 12 months in the best prognostic group (specificity 68.7% compared with 48.1% for the updated breast-GPA and 21.8% for the original GPA). Sensitivities for predicting 3 months survival were very low for all scores. In this analysis, all GPA-scores showed only moderate diagnostic accuracy in predicting the OS of BC patients with BM.
为了通过客观标准评估脑转移瘤(BM)患者的预后,已经开发了多种评分系统。本分析的目的是在德国乳腺癌脑转移(BMBC)登记处的882例患有BM的乳腺癌(BC)患者亚组中验证所有三种已发表的分级预后评估(GPA)评分。诊断BM时的中位年龄为57岁。总体而言,22.3%的患者(n = 197)为三阴性,33.4%(n = 295)为腔面A型,25.1%(n = 221)为腔面B/HER2富集型,19.2%(n = 169)为HER2阳性型BC。在单因素分析中,年龄≥60岁、颅外转移(ECM)证据、BM数量较多、三阴性亚型和低卡诺夫斯基表现状态(KPS)均与较差的总生存期(OS)相关(均P < 0.001)。所有三种GPA评分均与OS相关。乳腺GPA在最佳预后组中对生存期超过12个月的患者进行分类的概率最高(特异性为68.7%,而更新后的乳腺GPA为48.1%,原始GPA为21.8%)。所有评分预测3个月生存期的敏感性都非常低。在本分析中,所有GPA评分在预测患有BM的BC患者的OS方面仅显示出中等的诊断准确性。